FDA approves registration of AbSorber's transplantation test

Press release
August 12, 2008

FDA approves registration of AbSorber's transplantation test

LinkMed's portfolio company AbSorber has received clearance from the U.S. Food
and Drug Administration (FDA) to market and sell its XM-ONE® transplantation
test in the U.S. Initially, XM-ONE® sales in the U.S. will target the kidney
transplantation market valued at approximately SEK 200 million. XM-ONE®
previously received CE marking and is approved for sales within the EU.

AbSorber's transplantation test provides enhanced diagnostic value compared to
existing tests and facilitates matching the right organ with the right patient,
thereby increasing the probability of a successful transplantation.

”Approval from the FDA demonstrates that AbSorber and the XM-ONE®
transplantation test meet the tough requirements of the U.S. market. Now we can
market and sell XM-ONE® full on in the U.S. initially focusing on the kidney
transplantation segment, followed by a next step into the heart and lung
transplantation segment,” said LinkMed's CEO Ingemar Lagerlöf.
XM-ONE® is unique in that it is the first standardized test that can detect
antibodies against the cells that line the inside of blood vessels. These
endothelial cells are the first point of contact between the transplanted organ
and the recipient's immune system. Anti-endothelial cell antibodies have been
shown to play a key role in post-transplantation rejection reactions.

”This is why it is of the utmost importance that every available kidney for
transplantation is utilized properly, that is to say that the right kidney is
matched with the right recipient.  The total number of kidney transplantations
per year globally is 56,000 of which 17,000 take place in the USA. This makes
the U.S. the single largest market in the world,” said AbSorber‘s CEO Anders
Karlsson.

AbSorber has established good contact with ten renowned transplantation centers
in the U.S. Of these, four centers - Johns Hopkins University Hospital, Baylor
University Medical Center, The Ohio State University Medical Center and Mass.
General Hospital - have participated in a multicenter clinical trial of XM-ONE®
together with the Karolinska University Hospital and the Sahlgrenska University
Hospital. The results of the study are being published in conjunction with the
global congress for transplantations in Sydney in the middle of August. In
total, there are approximately 200 transplantation clinics in the U.S.

”Interest in XM-ONE® in the U.S. market is already considerable and the first
orders are expected shortly,” said Karlsson.

For LinkMed, with an ownership stake of 40 percent in AbSorber, the FDA approval
entails a breakthrough for the portfolio company that has come furthest in its
development. LinkMed, together with innovators, develops life science companies
and has been involved in AbSorber's development for the past eight years. In
2007, AbSorber had sales of approximately SEK 4 million. This figure is now
expected to increase quickly.LinkMed's position in the transplantation segment
is further strengthened by AbSorber's successes. In the long-term LinkMed will
strive to build a larger company in the transplantation segment with a broad
product portfolio.

Earlier this summer LinkMed acquired 100 percent of Olerup SSP AB, a world
leading company in the transplantation market and one of Sweden's most
profitable biotech companies. Olerup develops HLA typing tests that are
primarily used prior to bone-marrow transplantations.  XM-ONE® and Olerup's
products complement each other and target the same customers.

“In the long term, we will strive to build a larger company in the
transplantation segment with a broad product portfolio,” said Lagerlöf.

For more  information:
Anders Karlsson, CEO AbSorber, tel: + 46 70 918 00 10
Ingemar Lagerlöf, CEO LinkMed, tel: +46 8 508 939 93
Also visit  www.absorber.se and www.linkmed.se



LinkMed, in collaboration with innovators, develops life science companies. By
contributing entrepreneurship and capital, LinkMed has created a portfolio of
twelve companies, six in biotechnology and six in medical technology. The
company's principal owners are FastPartner, Koncentra Holding, and the founder
Ingemar Lagerlöf. The LinkMed share is listed on the OMX Nordic Exchange
Stockholm in the small-cap sector (ticker:LMED). 

AbSorber develops products that facilitate more successful transplantations.
AbSorber's first product, the transplantation test XM-ONE®, detects key
antibodies responsible for post-transplantation rejection reactions. XM-ONE® is
already CE marked and approved for sales in the EU.